For Industry

Public Meeting on Pulmonary Arterial Hypertension Patient-Focused Drug Development

On May 13, 2014, FDA conducted a public meeting on Pulmonary Arterial Hypertension Patient-Focused Drug Development. FDA is interested in obtaining patient input on the impact of pulmonary arterial hypertension on daily life and patients’ views on currently available therapies to treat the condition.

This website will be updated as meeting materials are developed.  

Date:May 13, 2014
Time:1:00 p.m. to 5:00 p.m.
Location:FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503A  (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA's White Oak campus)                
Registration
To register for this meeting, visit: http://patientfocusedpulmonaryarterialhypertension.eventbrite.com
Registration closed on April 30, 2014
 

Submitting comments to the docket: In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on July 14, 2014.

Webcast Recording

 

Page Last Updated: 12/11/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.